Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
CV-4151 may prolong bleeding time with antithrombotics in rats; leaves open any clinical translation or safety implications.
Effect of CV-4151, a thromboxane A2 synthase inhibitor, on antithrombotic and thrombolytic agents-induced bleeding time prolongation was examined in rats. CV-4151, ticlopidine, ozagrel and warfarin singly at doses greater than 0.3, 300, 1 and 0.5mg/kg, p. o. respectively, significantly prolonged bleeding time. Aspirin (10mg/kg, p. o.) also prolonged bleeding time. Tissue-type plasminogen activator (TPA, 2×104 IU/kg/min i. v. infusion) and urokinase (UK, 4×104IU/kg/min i. v. infusion) showed significant prolongation of bleeding time. Prologing effect of CV-4151 on bleeding time was weaker than those of warfarin and thrombolytic agents.In combined experiments with CV-4151 and other agents, CV-4151 moderately enhanced ticlopidine-induced bleeding time prolongation, and markedly enhanced warfarin-, TPA-and UK-induced bleeding time prolongation. On the other hand, CV-4151 had no effect on aspirin-induced bleeding time prolongation.Thus, CV-4151 markedly enhanced bleeding time prolongation caused by an oral anticoagulant and thrombolytic agents in rats.
No takes yet. Share an insight, caveat, or question.
Imura et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: